Nrf2-siRNA Enhanced the Anti-Tumor Effects of As₂O₃ in 5-Fluorouracil-Resistant Hepatocellular Carcinoma by Inhibiting HIF-1α/HSP70 Signaling

References

• Zhou HM, Zhang JG, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021;6(1):62.
   PubMed Web of Science ®Google Scholar
• Assaraf YG, Brozovic A, Goncalves AC, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 2019;46:100645. doi:10.1016/j.drup.2019.100645
   PubMed Web of Science ®Google Scholar
• Kartal-Yandim M, Adan-Gokbulut A, Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 2016;36(4):716–726. doi:10.3109/07388551.2015.1015957
   PubMed Web of Science ®Google Scholar
• Baguley BC. Multidrug resistance in cancer. Methods Mol Biol. 2010;596:1–14.
   PubMedGoogle Scholar
• Lee HA, Chu KB, Moon EK, Kim SS, Quan FS. Sensitization to oxidative stress and G2/M cell cycle arrest by histone deacetylase inhibition in hepatocellular carcinoma cells. Free Radic Biol Med. 2020;147:129–138. doi:10.1016/j.freeradbiomed.2019.12.021
   PubMed Web of Science ®Google Scholar
• Jin M, Yang Y, Dai Y, et al. 27-hydroxycholesterol is a specific factor in the neoplastic microenvironment of HCC that causes MDR via GRP75 regulation of the redox balance and metabolic reprogramming. Cell Biol Toxicol. 2021. doi:10.1007/s10565-021-09607-y
   Web of Science ®Google Scholar
• Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. 2009;44(Suppl 19):136–141. doi:10.1007/s00535-008-2252-z
   PubMed Web of Science ®Google Scholar
• Lee YG, Jeon TI. Modulation of the autophagy-lysosomal pathway in hepatocellular carcinoma using small molecules. Molecules. 2020;25(7):1580.
   PubMed Web of Science ®Google Scholar
• Hui F, Xu C, Xu X, et al. What is the most suitable agent combined with apatinib for transarterial chemoembolization treatment in advanced hepatocellular carcinoma patients? A systematic review and network meta-analysis. Front Oncol. 2022;12:887332.
   PubMed Web of Science ®Google Scholar
• Guo J, Huang L. Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. Nat Protoc. 2022;17(8):1818–1831. doi:10.1038/s41596-022-00698-3
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68–77. doi:10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013;65:750–764. doi:10.1016/j.freeradbiomed.2013.06.041
   PubMed Web of Science ®Google Scholar
• Sajadimajd S, Khazaei M. Oxidative stress and cancer: the role of Nrf2. Curr Cancer Drug Targets. 2018;18(6):538–557. doi:10.2174/1568009617666171002144228
   PubMed Web of Science ®Google Scholar
• Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, Leon R. Nrf2-ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol Ther. 2016;157:84–104. doi:10.1016/j.pharmthera.2015.11.003
   PubMed Web of Science ®Google Scholar
• Sebestyén A, Kopper L, Dankó T, Tímár J. Hypoxia signaling in cancer: from basics to clinical practice. Pathol Oncol Res. 2021;27:1609802. doi:10.3389/pore.2021.1609802
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao Z, Yin Q, Zhang X. TTB protects astrocytes against oxygen-glucose deprivation/reoxygenation-induced injury via activation of Nrf2/HO-1 signaling pathway. Front Pharmacol. 2019;10:792. doi:10.3389/fphar.2019.00792
   PubMed Web of Science ®Google Scholar
• Duan X-H, Li H, Ren J-Z, et al. Hepatic arterial chemoembolization with arsenic trioxide eluting CalliSpheres microspheres versus lipiodol emulsion: pharmacokinetics and intratumoral concentration in a rabbit liver tumor model. Cancer Manag Res. 2019;11:9979–9988. doi:10.2147/CMAR.S199188
   PubMed Web of Science ®Google Scholar
• Duan X, Li H, Han X, et al. Antitumor properties of arsenic trioxide-loaded CalliSpheres® microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival. Am J Transl Res. 2020;12(9):5511–5524.
   PubMed Web of Science ®Google Scholar
• Duan X, Zhao G, Han X, et al. Arsenic trioxide-loaded CalliSpheres: in vitro study of drug release and antitumor activity, and in vivo study of pharmacokinetics, treatment efficacy and safety in liver cancer. Oncol Rep. 2021;46(1). doi:10.3892/or.2021.8075
   Web of Science ®Google Scholar
• Wang M, Zhao X, Zhu D, et al. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 2017;36(1):60. doi:10.1186/s13046-017-0533-1
   PubMed Web of Science ®Google Scholar
• Pu Y, Yan D, Tu L, et al. CDK inhibition reverses acquired 5-fluorouracil resistance in hepatocellular carcinoma cells. Dis Markers. 2022;2022:6907057. doi:10.1155/2022/6907057
   PubMed Web of Science ®Google Scholar
• Wu Y, Li Q, Chen XZ. Detecting protein-protein interactions by far Western blotting. Nat Protoc. 2007;2(12):3278–3284. doi:10.1038/nprot.2007.459
   PubMed Web of Science ®Google Scholar
• Wan G, Liu Y, Zhu J, et al. SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3beta/beta-catenin pathway. Cell Signal. 2019;59:1–12. doi:10.1016/j.cellsig.2019.03.004
   PubMed Web of Science ®Google Scholar
• Serna G, Simonetti S, Fasani R, et al. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. Breast. 2020;53:102–110. doi:10.1016/j.breast.2020.07.002
   PubMed Web of Science ®Google Scholar
• Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv. 2013;31(8):1397–1407. doi:10.1016/j.biotechadv.2013.06.004
   PubMed Web of Science ®Google Scholar
• Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol. 2011;731:421–434.
   PubMedGoogle Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309. doi:10.1038/s41586-019-1730-1
   PubMed Web of Science ®Google Scholar
• Wahiduzzaman M, Ota A, Hosokawa Y. Novel mechanistic insights into the anti-cancer mode of arsenic trioxide. Curr Cancer Drug Targets. 2020;20(2):115–129. doi:10.2174/1568009619666191021122006
   PubMed Web of Science ®Google Scholar
• Kozono S, Lin YM, Seo HS, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018;9(1):3069. doi:10.1038/s41467-018-05402-2
   PubMed Web of Science ®Google Scholar
• Dong Y, Li X. Prospect of research and clinical application of arsenic compounds in chemotherapy for gynecological malignant tumors. Gynecol Obstet Clin Med. 2022;2(1):23–28. doi:10.1016/j.gocm.2022.01.001
   Google Scholar
• Zhang X, Hu B, Sun YF, et al. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021;11(2):e335. doi:10.1002/ctm2.335
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Y, Wang X, et al. Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. Cancer. 2015;121(17):2917–2925. doi:10.1002/cncr.29456
   PubMed Web of Science ®Google Scholar
• Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs. 2007;25(1):77–84. doi:10.1007/s10637-006-9004-9
   PubMed Web of Science ®Google Scholar
• Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Med Res Rev. 2022;42(1):374–398. doi:10.1002/med.21844
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang C, Zhang L, et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer. 2015;15:531. doi:10.1186/s12885-015-1541-1
   PubMed Web of Science ®Google Scholar
• Hong YB, Kang HJ, Kwon SY, et al. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas. 2010;39(4):463–472. doi:10.1097/MPA.0b013e3181c31314
   PubMed Web of Science ®Google Scholar
• Xue X, Zhao NY, Yu HT, et al. Discovery of novel inhibitors disrupting HIF-1alpha/von Hippel-Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016;4:e2757. doi:10.7717/peerj.2757
   PubMed Web of Science ®Google Scholar
• Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: a therapeutic target. World J Gastroenterol. 2015;21(42):12171–12178. doi:10.3748/wjg.v21.i42.12171
   PubMed Web of Science ®Google Scholar
• Takaki H, Hirata Y, Ueshima E, et al. Hepatic artery embolization enhances expression of programmed cell death 1 ligand 1 in an orthotopic rat hepatocellular carcinoma model: in vivo and in vitro experimentation. J Vasc Interv Radiol. 2020;31(9):1475–1482 e1472. doi:10.1016/j.jvir.2020.03.023
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang J, Lu Y, Luo Q, Zhu L. Nuclear respiratory factor-1 (NRF-1) regulated hypoxia-inducible factor-1alpha (HIF-1alpha) under hypoxia in HEK293T. IUBMB Life. 2016;68(9):748–755. doi:10.1002/iub.1537
   PubMed Web of Science ®Google Scholar
• Waghela BN, Vaidya FU, Pathak C. Upregulation of NOX-2 and Nrf-2 promotes 5-fluorouracil resistance of human colon carcinoma (HCT-116) cells. Biochemistry. 2021;86(3):262–274. doi:10.1134/S0006297921030044
   PubMed Web of Science ®Google Scholar
• Zheng J, Kim S-J, Saeidi S, et al. Overactivated NRF2 induces pseudohypoxia in hepatocellular carcinoma by stabilizing HIF-1α. Free Radic Biol Med. 2022. doi:10.1016/j.freeradbiomed.2022.11.039
   Web of Science ®Google Scholar
• Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998;52(6):1085–1090. doi:10.1016/S0090-4295(98)00360-4
   PubMed Web of Science ®Google Scholar
• Mirjolet JF, Barberi-Heyob M, Didelot C, et al. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer. 2000;83(10):1380–1386. doi:10.1054/bjoc.2000.1455
   PubMed Web of Science ®Google Scholar